# Relative Bioavailability/Bioequivalence of Different Formulations of Selinexor, the Impact of Hepatic Impairment on Selinexor Pharmacokinetics, Tolerability and Antitumor Activity of Selinexor Combination Treatment

> **NCT04256707** · PHASE1,PHASE2 · COMPLETED · sponsor: **Karyopharm Therapeutics Inc** · enrollment: 126 (actual)

## Conditions studied

- Non-Small Cell Lung Carcinoma (NSCLC)
- Colorectal Cancer (CRC)
- Other Solid Tumors

## Interventions

- **DRUG:** Selinexor 100 mg
- **DRUG:** Docetaxel
- **DRUG:** Pembrolizumab
- **DRUG:** FOLFIRI
- **DRUG:** Selinexor 40 mg
- **DRUG:** Selinexor 80 mg
- **DRUG:** Selinexor 60 mg

## Key facts

- **NCT ID:** NCT04256707
- **Lead sponsor:** Karyopharm Therapeutics Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-01-14
- **Primary completion:** 2024-07-31
- **Final completion:** 2024-07-31
- **Target enrollment:** 126 (ACTUAL)
- **Last updated:** 2025-03-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04256707

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04256707, "Relative Bioavailability/Bioequivalence of Different Formulations of Selinexor, the Impact of Hepatic Impairment on Selinexor Pharmacokinetics, Tolerability and Antitumor Activity of Selinexor Combination Treatment". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04256707. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*